Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity

(2022) Bo Meng et al.   NATURE

SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo

(2022) Kenrie P. Y. Hui et al.   NATURE

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

(2022) Emi Takashita et al.   NEW ENGLAND JOURNAL OF MEDICINE

Berbamine hydrochloride potently inhibits SARS-CoV-2 infection by blocking S protein-mediated membrane fusion

(2022) Zhe-Rui Zhang et al.   PLoS Neglected Tropical Diseases

Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19

(2021) Tzu-Chuan Ho et al.   Pathogens

Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment

(2021) Hirofumi Ohashi et al.   iScience

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

(2021) Venkata-Viswanadh Edara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2

(2021) Tia A. Tummino et al.   SCIENCE

Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytomorbidity-associated false positives

(2021) Kexin Yan et al.   Virology Journal

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

(2021) Vincent C Marconi et al.   Lancet Respiratory Medicine

SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells

(2021) Hanjun Zhao et al.   Emerging Microbes & Infections

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

(2020) Jia Liu et al.   Cell Discovery

SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology

(2020) Natacha S. Ogando et al.   JOURNAL OF GENERAL VIROLOGY

Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2

(2020) Markus Hoffmann et al.   NATURE

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

(2020) Laura Riva et al.   NATURE

Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2

(2020) Yuan-Lin Kang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

(S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1

(2017) Xuanxuan Dai et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Inhibition of cytosolic phospholipase A2α impairs an early step of coronavirus replication in cell culture

(2017) Christin Müller et al.   JOURNAL OF VIROLOGY

Identification of a Broad-Spectrum Antiviral Small Molecule against Severe Acute Respiratory Syndrome Coronavirus and Ebola, Hendra, and Nipah Viruses by Using a Novel High-Throughput Screening Assay

(2014) H. A. Elshabrawy et al.   JOURNAL OF VIROLOGY

Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy

(2014) Kilian V. M. Huber et al.   NATURE